Latest Market News

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Bannerman Energy reported a strong cash position of AUD 89.3 million at the end of December 2025, supported by significant equity financing and ongoing exploration investments. The company’s funding runway now extends to over nine quarters, providing a solid buffer for its uranium exploration activities.

Winsome Resources has agreed to be acquired by Li-FT Power Limited in a deal offering a substantial premium to shareholders, backed by strong lithium exploration results and strategic partnerships.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

Ionic Rare Earths has advanced its global rare earths strategy with a key US partnership, significant UK government funding, and progress in Brazil and Uganda, positioning itself as a critical player in sustainable magnet recycling and heavy rare earth supply.

Champion Iron Limited reported robust Q3 FY2026 results with record sales and ongoing progress on its DRPF project, while launching a significant acquisition offer for Rana Gruber.

Microba Life Sciences reports a 90% year-on-year increase in core microbiome test volumes, driving a 123% rise in core testing revenue to $2.1 million, while advancing clinical adoption and cost efficiencies.

First Graphene and UK manufacturer FP McCann have successfully produced the first batch of graphene-enhanced concrete roof tiles, marking a significant step toward low-carbon, high-performance construction materials in the UK housing sector.

Broken Hill Mines has delivered a standout December quarter with record mining rates at Rasp Mine, strong exploration results, and a robust financial position, setting the stage for accelerated growth in 2026.

Critical Resources Limited has secured a $1.75 million placement at market price, reinforcing investor confidence as it advances lithium, gold-antimony, and solid-state battery initiatives.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

Racura Oncology reported a transformative quarter with key scientific discoveries, expanded clinical programs, and a robust cash position of $20.94 million, setting the stage for pivotal cancer trials in 2026.